Compare AstraZeneca plc (AZN) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs State Street Technology Select Sector SPDR ETF — how do they compare? AstraZeneca plc trades at $158.76 (market cap $248.14B), while State Street Technology Select Sector SPDR ETF trades at $188.59. The key difference: AstraZeneca plc pays a 2.01% dividend while State Street Technology Select Sector SPDR ETF pays none, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | XLK | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $198.21 |
52-Week Low | $147.06 | $127.49 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
XLK trades at $188.86, up 1.36% with a bullish technical signal from moving averages. The ETF shows strong momentum near resistance at $189, supported by sector inflows and earnings growth. Recent news highlights tech sector leadership and investor accumulation during selloffs, though concentration risk remains a concern.
Outlook is positive with tech earnings driving gains, but overbought RSI and high dependence on mega-caps pose near-term risks. Long-term growth hinges on AI adoption and sector diversification, with analysts favoring broad tech exposure alternatives for valuation advantages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
